DiNAQOR, a Swiss-based genetic medicine platform company, announced on Thursday that it has named Mark Dehdashtian as its new executive vice president, Medical Devices.
In the new role, Dehdashtian will manage the company's newly established medical device division including its new manufacturing facility based in Laguna Hills, California and will be responsible for the design, development, and production of genetic medicine delivery devices for the firm's localised, catheter-based multi-organ access platform.
Dehdashtian has served Edwards Lifesciences for 25-year where he held various senior-level positions, including vice president of Research and Development for the Heart Valve Therapy, Advanced Technology and Cardiac Surgery Systems divisions. He was instrumental in commercialising the transcatheter heart valve transapical systems and holds over 60 United States patents and many international patents. He has served as a member of the medical technology steering committees to develop industry-wide standards.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval